19-38483329-C-T
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 0P and 0B.
This summary comes from the ClinGen Evidence Repository: This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions.This sequence variant predicts a substitution of arginine with cysteine at codon 1583 of the RYR1 protein, p.(Arg1583Cys). The maximum allele frequency (MAF) for this variant among the six major gnomAD populations is NFE: 0.000122, a frequency consistent with pathogenicity for MHS. However, the MAF in the Finnish population is 0.0014 which is higher than expected for a single pathogenic variant. This variant has been reported in two unrelated individuals who have a personal or family history of a malignant hyperthermia reaction and a positive in vitro contracture test (IVCT) or caffeine halothane contracture test (CHCT) result (if the proband was unavailable for testing, a positive diagnostic test result in a mutation-positive relative was counted); both of these individuals had a other RYR1 variants identified in cis (p.Gly248Arg and p.Glu5034Val, likely pathogenic and VUS, PMID:19346234; p.Val2102Leu, VUS, PMID:23035052). A third individual was identified with this variant and masseter muscle rigidity (PMID:30864471), a precursor to MH. The available case data combined with the high MAF in the NFE and FIN populations in gnomAD does not allow for the use of PS4. This variant segregates with MHS in two families, however, PP1 was not implemented due to the presence of other RYR1 variants in cis (PMID:19346234, PMID:23035052). Functional studies were carried out in B-lymphoblastoid cells from three family members with both the p.Arg1583Cys and p.Val2102Leu RYR1 variants (PMID:23035052). These cells were hypersensitive to agonist compared to wild type cells, however PS3 was not implemented as all cells were from the same family (two or more independent studies are required) and other variants in cis complicated the interpretation. This variant does not reside in a hotspot for pathogenic variants that contribute to MHS. A REVEL score of 0.586 supports neither a pathogenic nor a benign status for this variant. This variant has been classified as a Variant of Unknown Significance. No criteria implemented. LINK:https://erepo.genome.network/evrepo/ui/classification/CA081610/MONDO:0018493/012
Frequency
Consequence
NM_000540.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 0 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
RYR1 | NM_000540.3 | c.4747C>T | p.Arg1583Cys | missense_variant | 33/106 | ENST00000359596.8 | NP_000531.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
RYR1 | ENST00000359596.8 | c.4747C>T | p.Arg1583Cys | missense_variant | 33/106 | 5 | NM_000540.3 | ENSP00000352608 | A2 | |
RYR1 | ENST00000355481.8 | c.4747C>T | p.Arg1583Cys | missense_variant | 33/105 | 1 | ENSP00000347667 | P4 | ||
RYR1 | ENST00000599547.6 | c.4747C>T | p.Arg1583Cys | missense_variant, NMD_transcript_variant | 33/80 | 2 | ENSP00000471601 |
Frequencies
GnomAD3 genomes AF: 0.0000723 AC: 11AN: 152182Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000192 AC: 32AN: 166432Hom.: 0 AF XY: 0.000181 AC XY: 16AN XY: 88228
GnomAD4 exome AF: 0.000127 AC: 179AN: 1407652Hom.: 1 Cov.: 32 AF XY: 0.000122 AC XY: 85AN XY: 695234
GnomAD4 genome AF: 0.0000723 AC: 11AN: 152182Hom.: 0 Cov.: 32 AF XY: 0.0000807 AC XY: 6AN XY: 74344
ClinVar
Submissions by phenotype
not provided Uncertain:3
Uncertain significance, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Jul 22, 2019 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Athena Diagnostics | Dec 30, 2019 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Aug 18, 2015 | - - |
Malignant hyperthermia of anesthesia Uncertain:1Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jun 14, 2016 | - - |
Uncertain significance, reviewed by expert panel | curation | ClinGen Malignant Hyperthermia Susceptibility Variant Curation Expert Panel, ClinGen | Apr 06, 2023 | This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions. This sequence variant predicts a substitution of arginine with cysteine at codon 1583 of the RYR1 protein, p.(Arg1583Cys). The maximum allele frequency (MAF) for this variant among the six major gnomAD populations is NFE: 0.000122, a frequency consistent with pathogenicity for MHS. However, the MAF in the Finnish population is 0.0014 which is higher than expected for a single pathogenic variant. This variant has been reported in two unrelated individuals who have a personal or family history of a malignant hyperthermia reaction and a positive in vitro contracture test (IVCT) or caffeine halothane contracture test (CHCT) result (if the proband was unavailable for testing, a positive diagnostic test result in a mutation-positive relative was counted); both of these individuals had a other RYR1 variants identified in cis (p.Gly248Arg and p.Glu5034Val, likely pathogenic and VUS, PMID:19346234; p.Val2102Leu, VUS, PMID:23035052). A third individual was identified with this variant and masseter muscle rigidity (PMID:30864471), a precursor to MH. The available case data combined with the high MAF in the NFE and FIN populations in gnomAD does not allow for the use of PS4. This variant segregates with MHS in two families, however, PP1 was not implemented due to the presence of other RYR1 variants in cis (PMID:19346234, PMID:23035052). Functional studies were carried out in B-lymphoblastoid cells from three family members with both the p.Arg1583Cys and p.Val2102Leu RYR1 variants (PMID:23035052). These cells were hypersensitive to agonist compared to wild type cells, however PS3 was not implemented as all cells were from the same family (two or more independent studies are required) and other variants in cis complicated the interpretation. This variant does not reside in a hotspot for pathogenic variants that contribute to MHS. A REVEL score of 0.586 supports neither a pathogenic nor a benign status for this variant. This variant has been classified as a Variant of Unknown Significance. No criteria implemented. - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Dec 27, 2023 | Variant summary: RYR1 c.4747C>T (p.Arg1583Cys) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.00019 in 166432 control chromosomes (gnomAD). The observed variant frequency is approximately 2.2 fold of the estimated maximal expected allele frequency for a pathogenic variant in RYR1 causing Malignant Hyperthermia Susceptibility phenotype (8.8e-05), strongly suggesting that the variant is benign. c.4747C>T has been reported in the literature in individuals affected with Malignant Hyperthermia Susceptibility or Hypotonia without strong evidence of causality (e.g. Broman_2009, Schiemann_2013, Hudig_2019, Ek_2023). These reports do not provide unequivocal conclusions about association of the variant with Malignant Hyperthermia Susceptibility. Co-occurrence with another pathogenic variant was reported in affected individuals in one of these families (RYR1, p.Gly248Arg, Broman_2009), providing supporting evidence for a benign role. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 19346234, 23035052, 30864471, 37510298, 37273706). Seven submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. Six submitters classified it as uncertain significance, including a ClinGen expert panel, and one classified it as likely benign. Based on the evidence outlined above, the variant was classified as uncertain significance. - |
RYR1-related disorder Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Feb 11, 2022 | This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 1583 of the RYR1 protein (p.Arg1583Cys). This variant is present in population databases (rs754476250, gnomAD 0.2%). This missense change has been observed in individual(s) with clinical features of RYR1-related conditions (PMID: 19346234, 23035052). ClinVar contains an entry for this variant (Variation ID: 329032). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Congenital myopathy with fiber type disproportion;C0751951:Central core myopathy;C1840365:King Denborough syndrome;C1850674:Congenital multicore myopathy with external ophthalmoplegia;C2930980:Malignant hyperthermia, susceptibility to, 1 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Aug 10, 2021 | - - |
Central core myopathy Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jun 14, 2016 | - - |
Multiminicore myopathy Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jun 14, 2016 | - - |
Neuromuscular disease, congenital, with uniform type 1 fiber Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jun 14, 2016 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at